Avastin and Tarceva for Upper Gastrointestinal Cancers
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Erlotinib and bevacizumab have shown activity individually, as single drugs, or in
combination with chemotherapy in upper gastro-intestinal cancers, including esophageal and
gastro-esophageal adenocarcinomas, gastric cancer and pancreatic cancer. Biomarkers
indicating an important role of EGF and VEGF have been found in these tumors, and in
cholangiocarcinomas as well. There is promise that combined treatment with erlotinib and
bevacizumab is active and tolerable in a broad range of upper gastro-intestinal cancers,
justifying an experimental phase II-study of patients with these diagnoses, refractory or
intolerant to standard systemic therapy.